WO2007028135A3 - Imidazopyridine compounds - Google Patents
Imidazopyridine compounds Download PDFInfo
- Publication number
- WO2007028135A3 WO2007028135A3 PCT/US2006/034441 US2006034441W WO2007028135A3 WO 2007028135 A3 WO2007028135 A3 WO 2007028135A3 US 2006034441 W US2006034441 W US 2006034441W WO 2007028135 A3 WO2007028135 A3 WO 2007028135A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- imidazopyridine compounds
- compounds
- imidazopyridine
- glucokinase
- kits
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01001—Hexokinase (2.7.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
Abstract
Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06802913A EP1940837B1 (en) | 2005-09-01 | 2006-09-01 | Imidazopyridine compounds |
US12/065,607 US8124617B2 (en) | 2005-09-01 | 2006-09-01 | Imidazopyridine compounds |
JP2008529362A JP2009507039A (en) | 2005-09-01 | 2006-09-01 | Imidazopyridine compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-254194U | 2005-09-01 | ||
JP2005254194A JP2007063225A (en) | 2005-09-01 | 2005-09-01 | Imidazopyridine compound |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007028135A2 WO2007028135A2 (en) | 2007-03-08 |
WO2007028135A3 true WO2007028135A3 (en) | 2007-11-01 |
Family
ID=37925812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/034441 WO2007028135A2 (en) | 2005-09-01 | 2006-09-01 | Imidazopyridine compounds |
Country Status (4)
Country | Link |
---|---|
US (1) | US8124617B2 (en) |
EP (1) | EP1940837B1 (en) |
JP (2) | JP2007063225A (en) |
WO (1) | WO2007028135A2 (en) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007063225A (en) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | Imidazopyridine compound |
RU2009108280A (en) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use |
US8318746B2 (en) | 2007-04-27 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Nitrogen-containing five-membered heterocyclic compound |
WO2009022179A2 (en) * | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
EP2674417A3 (en) * | 2007-11-21 | 2014-04-09 | Decode Genetics EHF | Biaryl PDE4 inhibitors for treating inflammation |
WO2009082152A2 (en) | 2007-12-20 | 2009-07-02 | Lg Life Sciences Ltd. | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient |
WO2009128481A1 (en) * | 2008-04-16 | 2009-10-22 | 武田薬品工業株式会社 | Nitrogenated 5-membered heterocyclic compound |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
TW201014850A (en) | 2008-09-25 | 2010-04-16 | Takeda Pharmaceutical | Solid pharmaceutical composition |
JP5535931B2 (en) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | Bicyclic compound |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US8557805B2 (en) | 2008-12-29 | 2013-10-15 | Takeda Pharmaceutical Company Limited | Fused ring compound and use thereof |
WO2010111436A2 (en) * | 2009-03-25 | 2010-09-30 | Abbott Laboratories | Antiviral compounds and uses thereof |
EP2440541A1 (en) | 2009-06-09 | 2012-04-18 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
IN2012DN00954A (en) | 2009-07-28 | 2015-04-10 | Takeda Pharmaceutical | |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
KR101134194B1 (en) * | 2009-12-03 | 2012-04-09 | 서울대학교산학협력단 | Method of preparing hetero-biaryl pyridine derivative compounds, and hetero-biaryl pyridine derivative compounds prepared thereby |
CN102762564B (en) * | 2010-02-26 | 2015-09-30 | 拉夸里亚创药株式会社 | Be used for the treatment of cachectic Pueraria lobota Rayleigh receptor stimulant |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
JP5693611B2 (en) | 2010-04-27 | 2015-04-01 | 武田薬品工業株式会社 | Bicyclic compound |
GEP20146195B (en) | 2010-06-16 | 2014-11-10 | Takeda Pharmaceuticals Co | Crystal of amide compound |
EP2582709B1 (en) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
WO2011158149A1 (en) | 2010-06-18 | 2011-12-22 | Pfizer Inc. | 2-(3,5-disubstitutedphenyl)pyrimidin-4(3h)-one derivatives |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2012020725A1 (en) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Heterocyclic derivative having npy y5 receptor antagonism |
EP2617726A4 (en) | 2010-09-17 | 2014-05-14 | Takeda Pharmaceutical | Diabetes therapeutic agent |
US8729102B2 (en) | 2010-11-30 | 2014-05-20 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
KR20140015371A (en) | 2011-02-17 | 2014-02-06 | 다케다 야쿠힌 고교 가부시키가이샤 | Production method of optically active dihydrobenzofuran derivative |
EP2683699B1 (en) | 2011-03-08 | 2015-06-24 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
GB201104153D0 (en) * | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CA2853221A1 (en) | 2011-10-24 | 2013-05-02 | Tohru Yamashita | Bicyclic compound |
WO2013105676A1 (en) | 2012-01-12 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as mch receptor antagonists |
WO2013122029A1 (en) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | Aromatic ring compound |
WO2013122028A1 (en) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | Aromatic ring compound |
WO2013122260A1 (en) | 2012-02-15 | 2013-08-22 | Takeda Pharmaceutical Company Limited | Tablet |
JP6106179B2 (en) | 2012-02-24 | 2017-03-29 | 武田薬品工業株式会社 | Aromatic ring compounds |
WO2013147026A1 (en) | 2012-03-29 | 2013-10-03 | 武田薬品工業株式会社 | Aromatic ring compound |
WO2013168759A1 (en) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | Aromatic ring compound |
WO2013168760A1 (en) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | Aromatic ring compound |
CA2874820C (en) | 2012-06-05 | 2020-06-09 | Takeda Pharmaceutical Company Limited | Disintegrable and preservation stable solid preparation |
JP2015127299A (en) | 2012-07-19 | 2015-07-09 | 武田薬品工業株式会社 | Solid preparation |
GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
JP6247697B2 (en) | 2013-03-14 | 2017-12-13 | 武田薬品工業株式会社 | Spiroazetidine isoxazole derivatives and their use as SSTR5 antagonists |
US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9233961B2 (en) | 2013-03-15 | 2016-01-12 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
WO2015005489A1 (en) | 2013-07-09 | 2015-01-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015020184A1 (en) | 2013-08-09 | 2015-02-12 | 武田薬品工業株式会社 | Aromatic compound |
JO3442B1 (en) | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | Antagonists of somatostatin receptor subtype 5 (sstr5) |
AU2014364565B2 (en) | 2013-12-19 | 2017-06-15 | Novartis Ag | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
WO2016034671A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors |
WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
JP6629884B2 (en) | 2015-02-02 | 2020-01-15 | カンセラ・アーベー | 2-phenyl-3H-imidazo [4,5-B] pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ROR1 activity |
GB201604031D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604030D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
US11660303B2 (en) | 2016-07-11 | 2023-05-30 | Kancera Ab | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity |
US11008318B2 (en) | 2016-07-11 | 2021-05-18 | Kancera Ab | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity |
WO2018174170A1 (en) | 2017-03-23 | 2018-09-27 | 住友化学株式会社 | Fused heterocyclic compound and composition containing same |
JOP20180029A1 (en) | 2017-03-30 | 2019-01-30 | Takeda Pharmaceuticals Co | Heterocyclic compound |
CA3058578A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Aromatic compound |
AR111199A1 (en) | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | GPR40 AGONIST AROMATIC COMPOUND |
JOP20180028A1 (en) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | Peptide compound |
JP7205830B2 (en) * | 2017-08-07 | 2023-01-17 | 国立大学法人広島大学 | Novel anthranilic acid compound, and Pin1 inhibitor, therapeutic agent for inflammatory disease, and therapeutic agent for cancer using the same |
MX2020009950A (en) | 2018-03-23 | 2021-04-28 | Carmot Therapeutics Inc | Modulators of g-protein coupled receptors. |
WO2020045326A1 (en) | 2018-08-27 | 2020-03-05 | 株式会社スコヒアファーマ | Benzoic ester compound |
JP2022500483A (en) | 2018-09-24 | 2022-01-04 | 武田薬品工業株式会社 | GIP receptor agonist peptide compound and its use |
US20220135638A1 (en) | 2018-09-24 | 2022-05-05 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
KR20220157409A (en) | 2020-03-25 | 2022-11-29 | 다케다 야쿠힌 고교 가부시키가이샤 | GIP Receptor Agonist Peptide Compounds and Uses Thereof |
MX2022011816A (en) | 2020-03-25 | 2022-10-10 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof. |
BR112023023559A2 (en) | 2021-05-13 | 2024-02-06 | Carmot Therapeutics Inc | G PROTEIN COUPLED RECEPTOR MODULATORS |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1445824B1 (en) * | 1962-10-04 | 1969-11-13 | Geigy Ag J R | 1,3,4-thiadiazole derivatives and their use as nematocidal agents |
DE2305339A1 (en) * | 1973-02-03 | 1974-08-08 | Thomae Gmbh Dr K | 2-Phenyl-imidazo (4,5-b) pyridine derivs - prepared by reacting 2,3-diaminopyridines or 2-halo-3-amino-pyridines with benzoic acid derivs |
JP2001192653A (en) * | 1999-10-27 | 2001-07-17 | Fuji Photo Film Co Ltd | New fused heterocyclic compound, light emission element material and light emission element using the same |
WO2003026587A2 (en) * | 2001-09-26 | 2003-04-03 | Bristol-Myers Squibb Company | Compounds useful for treating hepatitus c virus |
EP1702919A1 (en) * | 2003-12-29 | 2006-09-20 | Banyu Pharmaceutical Co., Ltd. | Novel 2-heteroaryl-substituted benzimidazole derivative |
Family Cites Families (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3985891A (en) | 1973-02-03 | 1976-10-12 | Boehringer Ingelheim Gmbh | 2-Phenyl-imidazo (4,5-b)pyridines and salts thereof |
EP0072926B1 (en) * | 1981-08-19 | 1986-09-24 | MERCK PATENT GmbH | 2-arylimidazopyridines |
DE3132754A1 (en) * | 1981-08-19 | 1983-03-03 | Merck Patent Gmbh, 6100 Darmstadt | 2-Arylimidazo[4,5-b]pyridines, pharmaceutical preparations containing these compounds, and processes for their preparation |
JPS62232555A (en) | 1986-04-02 | 1987-10-13 | Unitika Ltd | Oxygen sensor |
US4959212A (en) | 1988-06-22 | 1990-09-25 | Alexandra Stancesco | Oxidizing-energizing composition and method for the treatment of diabetes |
US5239080A (en) | 1989-02-08 | 1993-08-24 | Takeda Chemical Industries, Ltd. | Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents |
US5541060A (en) | 1992-04-22 | 1996-07-30 | Arch Development Corporation | Detection of glucokinase-linked early-onset non-insulin-dependent diabetes mellitus |
DE69419639T2 (en) | 1993-03-17 | 1999-12-16 | Unitika Ltd | Process for the preparation of fructose 2,6-diphosphate and purification process therefor |
JP3203108B2 (en) | 1993-08-26 | 2001-08-27 | 協和メデックス株式会社 | Method for stabilizing glucose-6-phosphate dehydrogenase |
US6486380B1 (en) | 1993-12-17 | 2002-11-26 | University Of North Dakota Medical Education Research Foundation | Pancreatic β cell hexokinase transgene |
US7041503B2 (en) | 1995-05-02 | 2006-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Modified myelin basic protein molecules |
AU6944296A (en) | 1995-09-13 | 1997-04-01 | Takeda Chemical Industries Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
US5854067A (en) | 1996-01-19 | 1998-12-29 | Board Of Regents, The University Of Texas System | Hexokinase inhibitors |
GB9618934D0 (en) | 1996-09-11 | 1996-10-23 | Univ London | Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity |
WO2000053756A2 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2002008288A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6642360B2 (en) | 1997-12-03 | 2003-11-04 | Genentech, Inc. | Secreted polypeptides that stimulate release of proteoglycans from cartilage |
US20020032330A1 (en) | 1996-12-24 | 2002-03-14 | Yutaka Nomura | Propionic acid derivatives |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
EP1012188B1 (en) * | 1997-09-12 | 2004-08-18 | Pharis Biotec GmbH | Composition for treating diabetes mellitus and obesity |
US7378507B2 (en) | 1997-09-18 | 2008-05-27 | Genentech, Inc. | PRO217 polypeptides |
ZA988460B (en) | 1997-09-17 | 1999-03-19 | Genentech Inc | Polypeptides and nucleic acids encoding the same |
US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
AU1285499A (en) | 1997-10-30 | 1999-05-24 | Merck & Co., Inc. | Somatostatin agonists |
US6894148B2 (en) | 1997-11-12 | 2005-05-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030129691A1 (en) | 1998-02-09 | 2003-07-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20040048332A1 (en) | 1998-04-29 | 2004-03-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6232322B1 (en) * | 1998-05-12 | 2001-05-15 | American Home Products Corporation | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
US7339033B2 (en) | 1998-06-26 | 2008-03-04 | Genentech, Inc. | Pro1481 |
US20030073188A1 (en) | 1998-07-07 | 2003-04-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6242666B1 (en) | 1998-12-16 | 2001-06-05 | The Scripps Research Institute | Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells |
US20030190669A1 (en) | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
ATE374251T1 (en) | 1999-02-19 | 2007-10-15 | Engene Inc | COMPOSITIONS FOR GENE THERAPY OF DIABETES |
US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
MXPA01009814A (en) | 1999-03-29 | 2002-04-24 | Hoffmann La Roche | Glucokinase activators. |
US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
RU2242469C2 (en) | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Glucokinase activating agents |
US8193330B2 (en) | 1999-04-06 | 2012-06-05 | The Regents Of The University Of California | Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains |
US6967019B2 (en) | 1999-04-06 | 2005-11-22 | The Regents Of The University Of California | Production of pancreatic islet cells and delivery of insulin |
US6774120B1 (en) | 1999-06-01 | 2004-08-10 | Sarah Ferber | Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
DK1221444T3 (en) * | 1999-07-02 | 2005-11-14 | Eisai Co Ltd | Condensed imidazole compounds and anti-diabetes mellitus drugs |
AU7556800A (en) | 1999-10-07 | 2001-05-10 | Tadeka Chemical Industries, Ltd. | Amine derivatives |
JP4447705B2 (en) | 1999-10-20 | 2010-04-07 | 独立行政法人科学技術振興機構 | Diabetes onset model mammal |
US6620529B1 (en) | 1999-10-27 | 2003-09-16 | Fuji Photo Film Co., Ltd. | Materials for light emitting devices and light emitting devices using the same |
US20040072739A1 (en) | 1999-11-10 | 2004-04-15 | Anderson Christen M. | Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes |
SK6432002A3 (en) | 1999-11-10 | 2003-02-04 | Takeda Chemical Industries Ltd | 5-Membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
US6608038B2 (en) | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
US6716582B2 (en) | 2000-04-14 | 2004-04-06 | E. I. Du Pont De Nemours And Company | Cellular arrays for the identification of altered gene expression |
AU2001295841A1 (en) | 2000-04-25 | 2002-01-02 | German Human Genome Project | Human dna sequences |
WO2001082925A1 (en) | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonists |
CA2407416C (en) | 2000-05-03 | 2006-07-18 | Paige Erin Mahaney | Alkynyl phenyl heteroaromatic glucokinase activators |
ES2248309T3 (en) | 2000-05-03 | 2006-03-16 | F. Hoffmann-La Roche Ag | GLUCOQUINASE ACTIVATORS CONTAINING HYDANTOIN. |
AU6591401A (en) | 2000-05-08 | 2001-11-20 | Hoffmann La Roche | Para-amine substituted phenylamide glucokinase activators |
ES2230309T3 (en) | 2000-05-08 | 2005-05-01 | F. Hoffmann-La Roche Ag | PHENYLACETAMIDES REPLACED AND ITS EMPLOYMENT WITH QUCOKINASA ACTIVITIES. |
US6489485B2 (en) | 2000-05-08 | 2002-12-03 | Hoffmann-La Roche Inc. | Para-amine substituted phenylamide glucokinase activators |
US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
AU2001263360A1 (en) | 2000-05-19 | 2001-12-03 | Millennium Pharmaceuticals, Inc. | 50365, a hexokinase family member and uses thereof |
WO2001092523A2 (en) | 2000-05-30 | 2001-12-06 | Curagen Corporation | Human polynucleotides and polypeptides encoded thereby |
AU2001265231B2 (en) | 2000-05-31 | 2006-07-06 | Promega Corporation | Assay for kinases and phosphatases |
CA2412256A1 (en) | 2000-06-27 | 2002-01-03 | Curagen Corporation | Polynucleotides and polypeptides encoded thereby |
WO2002006339A2 (en) | 2000-07-03 | 2002-01-24 | Curagen Corporation | Proteins and nucleic acids encoding same |
WO2002008277A2 (en) | 2000-07-19 | 2002-01-31 | Eli Lilly And Company | Nucleic acids, vectors, host cells, polypeptides, and uses thereof |
ES2243547T3 (en) | 2000-07-20 | 2005-12-01 | F. Hoffmann-La Roche Ag | BENCENACETAMIDE REPLACED FOR ALFA-ACILO AND ALFA HETEROATOMOS AS A GLUCOKINASE ACTIVATOR. |
US20040044179A1 (en) | 2000-07-25 | 2004-03-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030100709A1 (en) | 2000-07-25 | 2003-05-29 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030105288A1 (en) | 2000-07-25 | 2003-06-05 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030212255A1 (en) | 2000-07-26 | 2003-11-13 | Muralidhara Padigaru | Novel proteins and nucleic acids encoding same |
WO2002014358A2 (en) | 2000-08-11 | 2002-02-21 | Eli Lilly And Company | Novel secreted proteins and their uses |
US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
WO2002014500A2 (en) | 2000-08-16 | 2002-02-21 | Chiron Corporation | Human genes and gene expression products |
AU2001284651A1 (en) | 2000-08-24 | 2002-03-04 | Eli Lilly And Company | Secreted proteins and methods of using same |
WO2002016599A2 (en) | 2000-08-25 | 2002-02-28 | Curagen Corporation | Proteins and nucleic acids encoding same |
US6346416B1 (en) | 2000-08-29 | 2002-02-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of HPK/GCK-like kinase expression |
US6849728B1 (en) | 2000-08-31 | 2005-02-01 | Wake Forest University Health Sciences | GLUT10: a glucose transporter in the type 2 diabetes linked region of chromosome 20Q12-13.1 |
CA2422068A1 (en) | 2000-09-13 | 2002-03-21 | Eleanor Roosevelt Institute | Method for treatment of insulin resistance in obesity and diabetes |
US20030187201A1 (en) | 2000-09-15 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2001290551A1 (en) | 2000-09-28 | 2002-04-08 | Eli Lilly And Company | Secreted proteins and their uses |
WO2002032939A2 (en) | 2000-10-19 | 2002-04-25 | Eli Lilly And Company | Secreted proteins and their uses |
WO2002057450A2 (en) | 2000-11-29 | 2002-07-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
AU2002227239A1 (en) | 2000-12-06 | 2002-06-18 | Curagen Corporation | Proteins and nucleic acids encoding same |
US6433188B1 (en) | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
KR100545431B1 (en) | 2000-12-06 | 2006-01-24 | 에프. 호프만-라 로슈 아게 | Fused heteroaromatic glucokinase activators |
EP1385953A2 (en) | 2000-12-08 | 2004-02-04 | Curagen Corporation | Proteins and nucleic acids encoding same |
US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
AU2002236440A1 (en) | 2000-12-15 | 2002-06-24 | Eli Lilly And Company | Novel secreted proteins and their uses |
JP2005508601A (en) | 2000-12-19 | 2005-04-07 | キュラジェン コーポレイション | Polypeptide and nucleic acid encoding it |
AU2002246808A1 (en) | 2000-12-19 | 2002-08-06 | Curagen Corporation | Human nucleic acids and polypeptides and methods of use thereof |
ES2170720B1 (en) | 2000-12-20 | 2003-12-16 | Univ Barcelona Autonoma | JOINT USE OF THE INSULIN GENE AND THE GLUCOQUINASE GENE IN THE DEVELOPMENT OF THERAPEUTIC APPROXIMATIONS FOR MELLITUS DIABETES. |
WO2002050277A2 (en) | 2000-12-21 | 2002-06-27 | Curagen Corporation | Protein and nucleic acids encoding same |
US7241579B2 (en) | 2000-12-22 | 2007-07-10 | Smithkline Beecham Corporation | Method of screening for GPR40 ligands |
EP1357186A4 (en) | 2000-12-28 | 2005-01-26 | Takeda Pharmaceutical | Novel proteins and dnas thereof |
US7122345B2 (en) | 2001-01-09 | 2006-10-17 | Curagen Corporation | Nucleic acid encoding a NOVX13 polypeptide |
CA2433742A1 (en) | 2001-01-11 | 2002-07-18 | Curagen Corporation | Proteins and nucleic acids encoding same |
JP4146095B2 (en) | 2001-01-15 | 2008-09-03 | ユニチカ株式会社 | Thermostable glucokinase gene, recombinant vector containing the same, transformant containing the recombinant vector, and method for producing thermostable glucokinase using the transformant |
JP2004525621A (en) | 2001-01-18 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Bifunctional fusion protein having glucocerebrosidase activity |
WO2002081517A2 (en) | 2001-01-19 | 2002-10-17 | Curagen Corporation | Novel polypeptides and nucleic acids encoded thereby |
GB0101447D0 (en) | 2001-01-19 | 2001-03-07 | Univ Edinburgh | Regulation of glucocorticoid concentration |
US20040081981A1 (en) | 2001-01-31 | 2004-04-29 | Toru Egashira | Method of detecting risk factor for onset of diabetes |
WO2002068649A2 (en) | 2001-01-31 | 2002-09-06 | Curagen Corporation | Proteins and nucleic acids encoding same |
US20040086875A1 (en) | 2001-11-05 | 2004-05-06 | Agee Michele L. | Novel proteins and nucleic acids encoding same |
US20040053245A1 (en) | 2001-02-05 | 2004-03-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6783969B1 (en) | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
WO2002072757A2 (en) | 2001-03-08 | 2002-09-19 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
CN1496412B (en) | 2001-03-14 | 2012-08-08 | 香港中文大学 | Method for estimating danger of diabetes typ B developed in the human species of Chinese bloodline and composition |
JP4602577B2 (en) | 2001-03-15 | 2010-12-22 | 積水メディカル株式会社 | Prediabetic screening method and screening reagent |
US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
US7186818B2 (en) | 2001-04-26 | 2007-03-06 | Immunex Corporation | DNA encoding soluble variants of human OX2 receptors |
AU2002259209A1 (en) | 2001-05-11 | 2002-11-25 | Adipogenix, Inc. | Methods and reagents for identifying insulin response modulators and therapeutic uses therefor |
CA2447015A1 (en) | 2001-05-15 | 2002-11-21 | Rappaport Family Institute For Research In The Medical Sciences | Insulin producing cells derived from human embryonic stem cells |
WO2002097434A1 (en) | 2001-05-29 | 2002-12-05 | Syddansk Universitet | Proteins in diabetes proteome analysis |
US20030092028A1 (en) | 2001-06-01 | 2003-05-15 | Yuanhong Ma | Methods and Reagents For Diagnosis and Treatment of Insulin Resistance and Related Condition |
AU2002315010A1 (en) | 2001-06-08 | 2002-12-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nucleic acid constructs useful for glucose regulated production of human insulin in somatic cell lines |
SE0102299D0 (en) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102300D0 (en) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
US20030120040A1 (en) | 2001-06-29 | 2003-06-26 | Genentech, Inc. | Secreted and Transmembrane polypeptides and nucleic acids encoding the same |
EP1409544B1 (en) | 2001-07-03 | 2009-06-17 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
SE0102764D0 (en) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
US20050245571A1 (en) | 2001-10-19 | 2005-11-03 | Hidenori Abe | Amine derivative |
WO2003047626A1 (en) | 2001-12-03 | 2003-06-12 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
US20030138416A1 (en) | 2001-12-03 | 2003-07-24 | Jesper Lau | Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
US20030023042A1 (en) | 2001-12-06 | 2003-01-30 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
DE10162730A1 (en) | 2001-12-20 | 2003-07-03 | Degussa | Alleles of the glk gene from coryneform bacteria |
CZ2004747A3 (en) | 2001-12-21 | 2004-11-10 | Novo Nordisk A/S | Amide derivatives functioning as GK activators |
WO2003075845A2 (en) | 2002-03-07 | 2003-09-18 | The Forsyth Institute | Immunogenicity of glucan binding protein |
EP1496052B1 (en) | 2002-03-26 | 2009-08-05 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
US20030232370A1 (en) | 2002-04-22 | 2003-12-18 | Trifiro Mark A. | Glucose sensor and uses thereof |
CA2482346C (en) | 2002-04-26 | 2010-03-09 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
AU2003235307A1 (en) | 2002-05-16 | 2003-12-02 | Banyu Pharmaceutical Co., Ltd. | Crystal of glucokinase protein, and method for drug design using the crystal |
US20060074018A1 (en) | 2002-06-04 | 2006-04-06 | Metabolex Inc | Methods of diagnosing & treating diabetes and insulin resistance |
CA2488568A1 (en) | 2002-06-04 | 2003-12-11 | Metabolex, Inc. | Methods of diagnosing and treating diabetes and insulin resistance |
AU2003243427A1 (en) | 2002-06-04 | 2003-12-19 | Metabolex, Inc. | Methods of diagnosing and treating diabetes and insulin resistance |
US20060234292A1 (en) | 2002-06-05 | 2006-10-19 | Bernard Allan | Methods of diagnosing and treating diabetes and insulin resistance |
CA2487943A1 (en) | 2002-06-05 | 2003-12-18 | Metabolex, Inc. | Methods of diagnosing & treating diabetes and insulin resistance |
JP2005529603A (en) | 2002-06-13 | 2005-10-06 | メタボレックス インコーポレーティッド | Compositions and methods for preventing, treating and diagnosing diabetes |
JP4881559B2 (en) | 2002-06-27 | 2012-02-22 | ノボ・ノルデイスク・エー/エス | Arylcarbonyl derivatives as therapeutic agents |
KR100442832B1 (en) | 2002-07-10 | 2004-08-02 | 삼성전자주식회사 | Primer sets for MODY2 gene amplification by multiplex polymerase chain reaction |
AU2003253880A1 (en) | 2002-07-15 | 2004-02-02 | Sugen, Inc. | Novel kinases |
US7087631B2 (en) | 2002-07-18 | 2006-08-08 | Inotek Pharmaceuticals Corporation | Aryltetrazole compounds, and compositions thereof |
US20040132679A1 (en) | 2002-09-03 | 2004-07-08 | Baylor College Of Medicine | Induction of pancreatic islet formation |
CA2498089A1 (en) | 2002-10-03 | 2004-06-17 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
AU2003270285B2 (en) | 2002-10-03 | 2007-04-26 | F. Hoffmann-La Roche Ag | Indole-3-carboxamides as glucokinase (GK) activators |
US20040108226A1 (en) | 2002-10-28 | 2004-06-10 | Constantin Polychronakos | Continuous glucose quantification device and method |
AU2003285069A1 (en) | 2002-10-28 | 2004-05-25 | Joslin Diabetes Center, Inc. | Type 2 diabetes mellitus genes |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
DE10258885A1 (en) | 2002-12-17 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Process for generating a genetically modified organism |
DK1585739T3 (en) | 2003-01-06 | 2011-06-20 | Lilly Co Eli | Substituted arylcyclopropylacetamides as glucokinase activators |
US7384965B2 (en) * | 2003-01-06 | 2008-06-10 | Eli Lilly And Company | Fused heterocyclic derivatives as PPAR modulators |
WO2004063194A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
WO2004069194A2 (en) | 2003-02-03 | 2004-08-19 | The Brigham And Women's Hospital, Inc. | Use of the oxidoreductase ncb50r for diagnosings and treating diabetes |
JP4621198B2 (en) | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | Tri (cyclo) substituted amide glucokinase activating compound |
PL378117A1 (en) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tri(cyclo) substituted amide compounds |
AU2004220234C1 (en) | 2003-02-13 | 2013-01-17 | Msd K.K. | Novel 2-pyridinecarboxamide derivatives |
EP1600442B1 (en) | 2003-02-26 | 2018-01-17 | Msd K.K. | Heteroarylcarbamoylbenzene derivative |
US7166692B2 (en) | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
US20040180845A1 (en) | 2003-03-13 | 2004-09-16 | Newgard Christopher B. | Methods and compositions for modulating glycogen synthesis and breakdown |
US20040185548A1 (en) | 2003-03-17 | 2004-09-23 | Qun-Sheng Ji | Hybrid receptors for efficient assay of modulators of receptor protein-tyrosine kinases |
US20040198969A1 (en) | 2003-04-01 | 2004-10-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7179613B2 (en) | 2003-05-05 | 2007-02-20 | Vanderbilt University | Methods of screening for a candidate modulator of glucokinase |
WO2004099246A2 (en) | 2003-05-09 | 2004-11-18 | Novo Nordisk A/S | Peptides for use in treating obesity |
US20050008691A1 (en) | 2003-05-14 | 2005-01-13 | Arturo Siles Ortega | Bicalutamide compositions |
DE602004022153D1 (en) | 2003-05-14 | 2009-09-03 | High Point Pharmaceuticals Llc | COMPOUNDS FOR THE TREATMENT OF OBESITAS |
CA2532807A1 (en) | 2003-07-17 | 2005-02-03 | Cotherix, Inc. | Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome |
AR048377A1 (en) | 2003-08-01 | 2006-04-26 | Janssen Pharmaceutica Nv | BENZOIMIDAZOL-, BENZOTRIAZOL- AND BENZOIMIDAZOLONA - O- SUBSTITUTED GLUCOSIDS |
CA2549017A1 (en) | 2003-08-01 | 2005-02-10 | Mona Patel | Substituted indazole-o-glucosides |
WO2005014532A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
US20070203059A1 (en) | 2003-09-22 | 2007-08-30 | Hutton John C | Targeted Drug-Formaldehyde Conjugates And Methods Of Making And Using The Same |
GB0325402D0 (en) * | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
EP1532980A1 (en) * | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
GB0327760D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
JP2005254194A (en) * | 2004-03-15 | 2005-09-22 | Yoshiteru Nakasaki | Environmental cleanup microreacter system |
EP1891069A1 (en) * | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
CA2617557A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
JP2007063225A (en) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | Imidazopyridine compound |
-
2005
- 2005-09-01 JP JP2005254194A patent/JP2007063225A/en not_active Revoked
-
2006
- 2006-09-01 US US12/065,607 patent/US8124617B2/en not_active Expired - Fee Related
- 2006-09-01 EP EP06802913A patent/EP1940837B1/en active Active
- 2006-09-01 WO PCT/US2006/034441 patent/WO2007028135A2/en active Application Filing
- 2006-09-01 JP JP2008529362A patent/JP2009507039A/en not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1445824B1 (en) * | 1962-10-04 | 1969-11-13 | Geigy Ag J R | 1,3,4-thiadiazole derivatives and their use as nematocidal agents |
DE2305339A1 (en) * | 1973-02-03 | 1974-08-08 | Thomae Gmbh Dr K | 2-Phenyl-imidazo (4,5-b) pyridine derivs - prepared by reacting 2,3-diaminopyridines or 2-halo-3-amino-pyridines with benzoic acid derivs |
JP2001192653A (en) * | 1999-10-27 | 2001-07-17 | Fuji Photo Film Co Ltd | New fused heterocyclic compound, light emission element material and light emission element using the same |
WO2003026587A2 (en) * | 2001-09-26 | 2003-04-03 | Bristol-Myers Squibb Company | Compounds useful for treating hepatitus c virus |
EP1702919A1 (en) * | 2003-12-29 | 2006-09-20 | Banyu Pharmaceutical Co., Ltd. | Novel 2-heteroaryl-substituted benzimidazole derivative |
Non-Patent Citations (1)
Title |
---|
YUTILOV Y M ET AL: "Preparation of 2-aryl-substituted derivatives of imidazo[4,5-b]pyridine and imidazo[4,5-c]pyridine", CHEMISTRY OF HETEROCYCLIC COMPOUNDS (A TRANSLATION OF KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII), PLENUM PRESS CO., NEW YORK, NY, US, no. 5, 1987, pages 639 - 645, XP002231885, ISSN: 0009-3122 * |
Also Published As
Publication number | Publication date |
---|---|
EP1940837A2 (en) | 2008-07-09 |
US20100069431A1 (en) | 2010-03-18 |
WO2007028135A2 (en) | 2007-03-08 |
JP2007063225A (en) | 2007-03-15 |
EP1940837B1 (en) | 2012-11-07 |
US8124617B2 (en) | 2012-02-28 |
JP2009507039A (en) | 2009-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007028135A3 (en) | Imidazopyridine compounds | |
WO2007061923A3 (en) | Glucokinase activators | |
WO2007075847A3 (en) | Glucokinase activators | |
WO2006044687A3 (en) | Kinase inhibitors | |
WO2006105127A3 (en) | Hydroxysteroid dehydrogenase inhibitors | |
MY146989A (en) | Kinase inhibitors | |
WO2007104034A3 (en) | Glucokinase activators | |
WO2008079787A3 (en) | Glucokinase activators | |
WO2006066109A3 (en) | Hydroxysteroid dehydrogenase inhibitors | |
WO2009156462A3 (en) | Organic compounds | |
WO2008055236A3 (en) | Mapk/erk kinase inhibitors | |
WO2008116107A3 (en) | Piperazine derivatives as glucokinase activators | |
WO2009079008A8 (en) | Benzopyrans and analogs as rho kinase inhibitors | |
WO2005074603A3 (en) | Aminobenzoxazoles as therapeutic agents | |
WO2007148185A3 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
WO2008079814A3 (en) | Mapk/erk kinase inhibitors | |
WO2008012532A3 (en) | : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase | |
WO2006122319A3 (en) | Histone deacetylase inhibitors | |
WO2007000339A8 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
WO2007117995A3 (en) | Kinase inhibitors | |
WO2008115890A3 (en) | Mapk/erk kinase inhibitors | |
WO2007133352A3 (en) | Macrocyclic kinase inhibitors | |
WO2007062308A3 (en) | Homo- and heterocyclic compounds suitable as cetp inhibitors | |
WO2006120563A3 (en) | Antibacterial agents | |
WO2008054956A3 (en) | Kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2008529362 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006802913 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06802913 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12065607 Country of ref document: US |